Your Trusted Brand for Over 35 Years

Bacterial Infections References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Howard BJ, Keisser JF, et al. Clinical and Pathogenic Microbiology . 2nd ed. St. Louis , Mo : Mosby; 1994.
  2. Murray PR, Rosenthal KS , et al. Medical Microbiology . 3rd ed. St. Louis , Mo : Mosby; 1998.
  3. Chandra RK. Nutritional regulation of immunity and risk of illness. Indian J Pediatr . 1989;56(5):607-11.
  4. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet . 1992a;340(8828):1124-7.
  5. Chandra RK. Nutrition and the immune system from birth to old age. Eur J Clin Nutr . 2002;56(suppl 3):73-6.
  6. Chandra RK. Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals. Ageing Res Rev . 2004;3(1):91-104.
  7. Hedlund J. Community-acquired pneumonia requiring hospitalization: factors of importance for the short- and long-term prognosis. Scand J Infect Dis Suppl . 1995;97:1-60.
  8. Hill AV. Human genetics and infection. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 5th ed. Philadelphia , Pa : Churchill Livingstone; 2000.
  9. Bentley DR . The Human Genome Project: an overview. Med Res Rev . 2000;20(3):189-96.
  10. Cariou A, Chiche JD, et al. The era of genomics: impact on sepsis clinical trial design. Crit Care Med. 2002 May;30(suppl 5):S341-S348.
  11. Madoff LC, Kasper DL. Introduction to infectious disease: host-pathogen interactions. In: Kasper DL, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill; 2004.
  12. Goldmann O, Chhatwal GS, et al. Immune mechanisms underlying host susceptibility to infection with group A streptococci. J Infect Dis . 2003;187(5):854-61.
  13. O'Brien KL, Beall B, et al. Epidemiology of invasive group A streptococcus disease in the United States : 1995-1999. Clin Infect Dis . 2002 Aug 1;35(3):268-76.
  14. Echave P, Bille J, et al. Percentage, bacterial etiology and antibiotic susceptibility of acute respiratory infection and pneumonia among children in rural Senegal . J Trop Pediatr . 2003;49(1):28-32.
  15. Robinson KA, Baughman W, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA . 2001;285(13):1729-35.
  16. Leibovitz E, Greenberg D. Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J . 2004;27(7):475-88.
  17. Garcia Ordonez MA, Alvarez Hurtado F, et al. Community-acquired bacteremic pneumonia in the elderly. An Med Interna . 1999 Jul;16(7):345-8.
  18. Dai G, Phalen S, et al. Nutritional modulation of host responses to mycobacteria. Front Biosci . 1998;3:110-22.
  19. Skamene E. Population and molecular genetics of susceptibility to tuberculosis. Clin Invest Med . 1991;14(2):160-6.
  20. Fleischmann RD , Alland D, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol . 2002;184(19):5479-90.
  21. Lobacheva T, Sazhin V, et al. Pulmonary tuberculosis in two remand prisons (SIZOs) in St Petersburg , Russia . Euro Surveill . 2005 Jun;10(6):93-6. Free full text at:
  22. National Institutes of Health (NIH). Accessed November 23, 2005. Available at:
  23. Marignani M, Angeletti S, et al. Acute infectious diarrhea. N Engl J Med . 2004;350(15):1576-7.
  24. Reinert P. Infections in malnourished infants and children. Dev Sante . 1993;103:4-6.
  25. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect . 2004 Oct;10(10):868-76.
  26. Moore JE, Corcoran D, et al. Campylobacter. Vet Res. 2005 May-Jun;36(3):351-82.
  27. Takkinen J, Ammon A. The 11th International Workshop of Campylobacter, Helicobacter and Related Organisms (CHRO): 2001. Euro Surveill. 2003 Nov;8(11):219-22.
  28. Kasper DL, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill; 2004.
  29. Gold HS, Eisenstein BI. Introduction to bacterial diseases. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 5th ed. Philadephia , Pa : Churchill Livingstone; 2000.
  30. Conte JE Jr. Manual of Antibiotics and Infectious Diseases: Treatment and Prevention . 9th ed . Philadelphia , Pa : Lippincott Williams & Wilkins; 2002.
  31. Basso D, Plebani M. H. pylori infection: bacterial virulence factors and cytokine gene polymorphisms as determinants of infection outcome. Crit Rev Clin Lab Sci . 2004;41(3):313-7.
  32. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther . 2002;16(suppl 1):3-15.
  33. Zambon CF, Basso D, et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine . 2002 Jun 7;18(5):242-51.
  34. Gelfand JA. Infections in burn patients: a paradigm for cutaneous infection in the patient at risk. Am J Med . 1984 May 15;76(5A):158-65.
  35. Baggett HC, Hennessy TW, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis . 2004 May 1;189(9):1565-73.
  36. Toshkova K, Annemuller C, et al. The significance of nasal carriage of Staphylococcus aureus as risk factor for human skin infections. FEMS Microbiol Lett . 2001;202(1):17-24.
  37. Wysocki AB. Evaluating and managing open skin wounds: colonization versus infection. AACN Clin Issues . 2002;13(3):382-97.
  38. Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med . 1991 Sep 16;91(3B):179S-184S.
  39. Weinstein RA. Nosocomial infection update. Emerg Infect Dis . 1998;4(3):416-20.
  40. Malone DL, Genuit T, et al. Surgical site infections: reanalysis of risk factors. J Surg Res . 2002;103(1):89-95.
  41. Tasota FJ, Fisher EM, et al. Protecting ICU patients from nosocomial infections: practical measures for favorable outcomes. Crit Care Nurse . 1998;18(1):54-65.
  42. Goldmann DA, Weinstein RA, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA . 1996;275(3):234-40.
  43. Archer GL, Polk RE. Treatment and prophylaxis of bacterial infections. In: Kasper DL, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill; 2004:
  44. Roden DM. Principles of clinical pharmacology. In: Kasper DL, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill; 2004.
  45. Barie PS. Antibiotic-resistant gram-positive cocci: implications for surgical practice. World J Surg . 1998;22(2):118-26.
  46. Domin MA. Highly virulent pathogens: a post antibiotic era? Br J Theatre Nurs . 1998;8(2):14-8.
  47. Petrosillo N, Pantosti A, et al. Prevalence, determinants, and molecular epidemiology of Streptococcus pneumoniae isolates colonizing the nasopharynx of healthy children in Rome . Eur J Clin Microbiol Infect Dis . 2002;21(3):181-8.
  48. van der Waaij D, Nord CE. Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int J Antimicrob Agents . 2000;16(3):191-7.
  49. Flaherty JP, Weinstein RA. Nosocomial infection caused by antibiotic-resistant organisms in the intensive-care unit. Infect Control Hosp Epidemiol . 1996;17(4):236-48.
  50. Jacobs MR. Drug-resistant Streptococcus pneumoniae: rational antibiotic choices. Am J Med . 1999;106(5A):19S-25S.
  51. Levin AS , Levy CE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents . 2003 Jan;21(1):58-62.
  52. Amsden GW. Pneumococcal resistance in perspective: how well are we combating it? Pediatr Infect Dis J . 2004;23(suppl 2):125-8.
  53. Apfalter P. MRSA/MRSE-VISA/GISA/VRSA-PRP-VRE: current gram positive problem bacteria and mechanism of resistance, prevalence and clinical consequences. Wien Med Wochenschr . 2003;153(7-8):144-7.
  54. Austin DJ, Bonten MJ, et al. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci U S A . 1999;96(12):6908-13.
  55. Bonten MJ, Willems R, et al. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis . 2001 Dec;1(5):314-25.
  56. Borer A, Gilad J, et al. Community-acquired methicillin-resistant Staphylococcus aureus in institutionalized adults with developmental disabilities. Emerg Infect Dis . 2002;8(9):966-70.
  57. Carson CF, Riley TV. Non-antibiotic therapies for infectious diseases. Commun Dis Intell . 2003;27(suppl):S143-S146.
  58. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet . 2003;361(9356):512-9.
  59. Briend A. Vitamin A and diarrhoea: reducing the risk? Dialogue Diarrhoea . 1988 Jun;33:4-5.
  60. Brunser O. Effects of malnutrition on intestinal structure and function in children. Clin Gastroenterol . 1977;6(2):341-53.
  61. Fontaine O. Dealing with diarrhoea. Child Health Dialogue . 1996;(3-4):5.
  62. Guerrant RL, Lima AA, et al. Micronutrients and infection: interactions and implications with enteric and other infections and future priorities. J Infect Dis . 2000;182(suppl 1):134-8.
  63. Calder PC, Kew S. The immune system: a target for functional foods? Br J Nutr . 2002;88(suppl 2):165-77.
  64. Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr . 1997 Aug;66(2):464S-477S.
  65. Scrimshaw NS. Historical concepts of interactions, synergism and antagonism between nutrition and infection. J Nutr . 2003 Jan;133(1):316S-321S.
  66. Chandra RK. Nutrition and immunology: from the clinic to cellular biology and back again. Proc Nutr Soc . 1999;58(3):681-3.
  67. Balentine DA, Albano MC, et al. Role of medicinal plants, herbs, and spices in protecting human health. Nutr Rev . 1999;57(pt 2):41-5.
  68. Craig W, Beck L. Phytochemicals: health protective effects. Can J Diet Pract Res . 1999a;60(2):78-84.
  69. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr . 1999b;70(suppl 3):491S-499S.
  70. Lampe JW. Health effects of vegetables and fruit: assessing mechanisms of action in human experimental studies. Am J Clin Nutr . 1999;70(suppl 3):475S-490S.
  71. Pugliese PT, Jordan K, et al. Some biological actions of alkylglycerols from shark liver oil. J Altern Complement Med . 1998;4(1):87-99.
  72. Mascolo N, Jain R, et al. Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol . 1989 Nov;27(1-2):129-40.
  73. Anon. Whey protein - monograph. Altern Med Rev. 2008 Dec;13(4):342-9.
  74. Lusby PE , Coombes A, et al. Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs . 2002;29(6):295-300.
  75. Miorin PL, Levy Junior NC, et al. Antibacterial activity of honey and propolis from Apis mellifera and Tetragonisca angustula against Staphylococcus aureus. J Appl Microbiol . 2003;95(5):913-20.
  76. Molan PC. Re-introducing honey in the management of wounds and ulcers: theory and practice. Ostomy Wound Manage . 2002;48(11):28-40.
  77. Boyanova L, Derejian S, et al. Inhibition of Helicobacter pylori growth in vitro by Bulgarian propolis: preliminary report. J Med Microbiol . 2003 May;52(pt 5):417-9.
  78. Dobrowolski JW, Vohora SB, et al. Antibacterial, antifungal, antiamoebic, anti-inflammatory and antipyretic studies on propolis bee products. J Ethnopharmacol . 1991;35(1):77-82.
  79. Grange JM, Davey RW. Antibacterial properties of propolis (bee glue). J R Soc Med . 1990;83(3):159-60.
  80. Engwerda CR, Andrew D, et al. Bromelain modulates T cell and B cell immune responses in vitro and in vivo. Cell Immunol. 2001 May 25;210(1):66-75.
  81. Mynott TL, Luke RK, et al. Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Gut. 1996 Jan;38(1):28-32.
  82. Mynott TL, Guandalini S, et al. Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Gastroenterology. 1997 Jul;113(1):175-84.
  83. Fleet JC. New support for a folk remedy: cranberry juice reduces bacteriuria and pyuria in elderly women. Nutr Rev . 1994;52(5):168-70.
  84. Kontiokari T, Sundqvist K, et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ . 2001 Jun 30;322(7302):1571.
  85. Pinzón-Arango PA, Liu Y, Camesano TA. Role of cranberry on bacterial adhesion forces and implications for Escherichia coli-uroepithelial cell attachment. J Med Food. 2009 Apr;12(2):259-70.
  86. Stothers L. A randomized placebo controlled trial to evaluate naturopathic cranberry products as prophylaxis against urinary tract infection in women. Presented at: American Urological Association 2001 Annual Meeting; June 2-7, 2001; Anaheim, CA; Publ ID:318.
  87. McMurdo ME, Argo I, Phillips G, Daly F, Davey P. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women. J Antimicrob Chemother. 2009 Feb;63(2):389-95.
  88. Allaert F. Double-blind, placebo-controlled study of Hibiscus sabdariffa L extract in the prevention of recurrent cystitis in women. Poster presented at the Federative Pelviperineal Diagnostics and Procedures Meeting: Convergences in Pelviperineal Pain. Nantes, France: December 16-18, 2009.
  89. Dadalioglu I, Evrendilek GA. Chemical compositions and antibacterial effects of essential oils of Turkish oregano, bay laurel, Spanish lavender, and fennel on common foodborne pathogens. J Agric Food Chem . 2004 Dec 29;52(26):8255-60.
  90. Preuss HG, Echard B, et al. Minimum inhibitory concentrations of herbal essential oils and monolaurin for gram-positive and gram-negative bacteria. Mol Cell Biochem. 2005 Apr;272(1-2):29-34.
  91. Marino M, Bersani C, et al. Antimicrobial activity of the essential oils of Thymus vulgaris L. measured using a bioimpedometric method. J Food Prot . 1999 Sep;62(9):1017-23.
  92. Faleiro L, Miguel G, et al. Antibacterial and antioxidant activities of essential oils isolated from Thymbra capitata L (Car.) and Origanum vulgare L. J Agric Food Chem . 2005 Oct 19;53(21):8162-8.
  93. Chrubasik S, Pittler MH, et al. Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 2005 Sep;12(9):684-701.
  94. Marshall K. Therapeutic applications of whey protein. Altern Med Rev. 2004 Jun;9(2):136-56.
  95. Thongson C, Davidson PM, et al. Antimicrobial activity of ultrasound-assisted solvent-extract spices. Lett Appl Microbiol . 2004;39(5):401-6.
  96. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN. N-acetyl cysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci. 2004 Nov-Dec;49(11-12):1853-61.
  97. Seo JY, Kim H, Kim KH. Transcriptional regulation by thiol compounds in Helicobacter pylori-induced interleukin-8 production in human gastric epithelial cells. Ann N Y Acad Sci. 2002 Nov;973:541-5.
  98. Kim MH, Yoo HS, Kim MY, et al. Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-kappaB signaling in human gastric carcinoma cells. Int J Mol Med. 2007 Apr;19(4):689-97.
  99. Zala G, Flury R, Wust J, Meyenberger C, Ammann R, Wirth HP. Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetyl cysteine. Schweiz Med Wochenschr. 1994 Aug 9;124(31-32):1391-7.
  100. Gurbuz AK, Ozel AM, Ozturk R, Yildirim S, Yazgan Y, Demirturk L. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J. 2005 Nov;98(11):1095-7.
  101. Bhaskaram P. Immunobiology of mild micronutrient deficiencies. Br J Nutr . 2001;85(suppl 2):75-80.
  102. Meydani SN, Erickson KL. Nutrients as regulators of immune function: introduction. Faseb J . 2001 Dec;15(14):2555.
  103. Murray MT , Pizzorno JE. Encyclopedia of Natural Medicine . 2nd ed. New York , NY : Three Rivers Press; 1997.
  104. Barringer TA, Kirk JK, et al. Effect of a multivitamin and mineral supplement on infection and quality of life: a randomized, double-blind, placebo-controlled trial. Ann Intern Med . 2003;138(5):365-71.
  105. MacKay D, Miller AL. Nutritional support for wound healing. Altern Med Rev . 2003 Nov;8(4):359-77.
  106. Bistrian BR. Practical recommendations for immune-enhancing diets. J Nutr . 2004 Oct;134(suppl 10):2868S-2878S.
  107. Aukrust P, Muller F, et al. Decreased vitamin A levels in common variable immunodeficiency: vitamin A supplementation in vivo enhances immunoglobulin production and downregulates inflammatory responses. Eur J Clin Invest . 2000;30(3):252-9.
  108. Cui D, Moldoveanu Z, et al. High-level dietary vitamin A enhances T-helper type 2 cytokine production and secretory immunoglobulin A response to influenza A virus infection in BALB/c mice. J Nutr . 2000 May;130(5):1132-9.
  109. Molina EL, Patel JA. A to Z: vitamin A and zinc, the miracle duo. Indian J Pediatr . 1996;63(4):427-31.
  110. Alberts D, Ranger-Moore J, et al. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res. 2004 Mar 15;10(6):1875-80.
  111. Tengerdy RP. The role of vitamin E in immune response and disease resistance. Ann N Y Acad Sci . 1990;587:24-33.
  112. Bogden JD. Influence of zinc on immunity in the elderly. J Nutr Health Aging . 2004;8(1):48-54.
  113. Cuevas LE, Koyanagi A. Zinc and infection: a review. Ann Trop Paediatr . 2005 Sep;25(3):149-60.
  114. Cunningham-Rundles S, Ahrne S, et al. Probiotics and immune response. Am J Gastroenterol . 2000;95(suppl 1):22-5.
  115. Stefanidou M, Maravelias C, et al. Zinc: a multipurpose trace element. Arch Toxicol. 2005 Sep 27;1-9.
  116. Chandra RK. Nutrition and immunoregulation: significance for host resistance to tumors and infectious diseases in humans and rodents. J Nutr . 1992b;122(suppl 3):754-7.
  117. Ankri S, Mirelman D. Antimicrobial properties of allicin from garlic. Microbes Infect . 1999;1(2):125-9.
  118. Cutler RR, Wilson P. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. Br J Biomed Sci . 2004;61(2):71-4.
  119. Jonkers D, van den Broek E, et al. Antibacterial effect of garlic and omeprazole on Helicobacter pylori. J Antimicrob Chemother . 1999;43(6):837-9.
  120. Sovova M, Sova P. Pharmaceutical importance of Allium sativum L, II: antibacterial effects. Ceska Slov Farm . 2002 Jan;51(1):11-6.
  121. Craig WJ. Phytochemicals: guardians of our health. J Am Diet Assoc . 1997;97(suppl 2):199-204.
  122. Harris JC, Cottrell SL, et al. Antimicrobial properties of Allium sativum (garlic). Appl Microbiol Biotechnol . 2001;57(3):282-6.
  123. Dikasso D, Lemma H, et al. Investigation on the antibacterial properties of garlic on pneumonia-causing bacteria. Ethiop Med J. 2002 Jul;40(3):241-9.
  124. Sivam GP. Protection again Helicobacter pylori and other bacterial infections by garlic. J Nutr. 2001 Mar;131(3s):1106S-1108S.
  125. Tsao SM, Hsu CC, et al. Garlic extract and two diallyl sulphides inhibit methicillin-resistant Staphylococcus aureus infection in BALB/cA mice. J Antimicrob Chemother . 2003 Dec;52(6):974-80.
  126. O'Hara M, Kiefer D, et al. A review of 12 commonly used medicinal herbs. Arch Fam Med . 1998;7(6):523-36.
  127. Sun D, Abraham SN, et al. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother . 1988 Aug;32(8):1274-7.
  128. Sack RB, Froehlich JL. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun . 1982;35(2):471-5.
  129. Chung JG. Inhibitory actions of glycyrrhizic acid on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Drug Chem Toxicol . 1998 Aug;21(3):355-70.
  130. Krausse R, Bielenberg J, et al. In vitro anti-Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites. J Antimicrob Chemother . 2004 Jul;54(1):243-6.
  131. Stormer FC, Reistad R, et al. Glycyrrhizic acid in liquorice: evaluation of health hazard. Food Chem Toxicol. 1993 Apr;31(4):303-12.
  132. de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, Rossi M, Marchi S. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007 May;102(5):951-6. Epub 2007 Feb 21.
  133. Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K, Yoshie H. Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob Agents Chemother. 2009 Aug;53(8):3308-16. Epub 2009 May 18.
  134. Hayworth JL, Kasper KJ, Leon-Ponte M, Herfst CA, Yue D, Brintnell WC, Mazzuca DM, Heinrichs DE, Cairns E, Madrenas J, Hoskin DW, McCormick JK, Haeryfar SM. Attenuation of massive cytokine response to the staphylococcal enterotoxin B superantigen by the innate immunomodulatory protein lactoferrin. Clin Exp Immunol. 2009 Jul;157(1):60-70.
  135. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol. 1992a Dec;73(6):472-9.
  136. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta. 1992b May 22;1121(1-2):130-6.
  137. Artym J. The role of lactoferrin in the iron metabolism. Part II. Antimicrobial and antiinflammatory effect of lactoferrin by chelation of iron. Postepy Hig Med Dosw (Online). 2010 Nov 30;64:604-16.
  138. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8. Epub 2008 Oct 7.
  139. Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie. 2009 Jan;91(1):11-8. Epub 2008 May 21.
  140. León-Sicairos N, López-Soto F, Reyes-López M, Godínez-Vargas D, Ordaz-Pichardo C, de la Garza M. Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme. Clin Med Res. 2006 Jun;4(2):106-13.
  141. Norrby K. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo. J Vasc Res. 2004 Jul-Aug;41(4):293-304. Epub 2004 Jun 10.
  142. Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004 Apr;49(4):579-89.
  143. Griffiths EA, Duffy LC, et al. In vitro growth responses of bifidobacteria and enteropathogens to bovine and human lactoferrin. Dig Dis Sci . 2003 Jul;48(7). 1324-32.
  144. Haversen LA, Engberg I, et al. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect Immun . 2000;68(10):5816-23.
  145. Baldi A, Ioannis P, et al. Biological effects of milk proteins and their peptides with emphasis on those related to the gastrointestinal ecosystem. J Dairy Res . 2005;72 Spec No:66-72.
  146. Kuwata H, Yip TT, et al. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun . 1998 Apr;245(3):764-73.
  147. Nikolaev AA, Boiko OV, et al. Ejaculate microflora sensitivity to lactoferrin in chronic prostatitis. Urologiia . 2004 Sep-Oct;5:37-9.
  148. Leitch EC, Willcox MD. Lactoferrin-induced reduction of vanB vancomycin resistance in enterococci. Int J Antimicrob Agents. 2001 Oct;18(4):399-402.
  149. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut . 1998;42(1):2-7.
  150. Dani C, Biadaioli R, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants: a prospective double-blind study. Biol Neonate . 2002;82(2):103-8.
  151. Perdigon G, Alvarez S, et al. Immune system stimulation by probiotics. J Dairy Sci . 1995;78(7):1597-606.
  152. Ochmanski W, Barabasz W. Probiotics and their therapeutic properties. Przegl Lek . 1999;56(3):211-5.
  153. Vaughan EE, Mollet B. Probiotics in the new millennium. Nahrung . 1999;43(3):148-53.
  154. Cremonini F, Canducci F, et al. Helicobacter pylori treatment: a role for probiotics? Dig Dis . 2001;19(2):144-7.
  155. Drouin E. Helicobacter pylori: novel therapies. Can J Gastroenterol . 1999;13(7):581-3.
  156. Felley C, Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol . 2003;17(5):785-91.
  157. Johnson-Henry KC, Mitchell DJ, et al. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci . 2004 Aug;49(7-8):1095-1102.
  158. Wang KY , Li SN, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004 Sep;80(3):737-41.
  159. Kontiokari T, Laitinen J, et al. Dietary factors protecting women from urinary tract infection. Am J Clin Nutr . 2003;77(3):600-4.
  160. Reid G. Probiotics for urogenital health. Nutr Clin Care . 2002a;5(1):3-8.
  161. Andreeva P, Dimitrov A. The probiotic Lactobacillus acidophilus: an alternative treatment of bacterial vaginosis. Akush Ginekol (Sofiia) . 2002;41(6):29-31.
  162. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr . 2002;88(suppl 1):39-49.
  163. Shi HN, Walker A. Bacterial colonization and the development of intestinal defences. Can J Gastroenterol . 2004 Aug;18(8):493-500.
  164. Trevisanato SI, Kim YI. Tea and health. Nutr Rev . 2000;58(1):1-10.
  165. Bukowski JF, Morita CT , et al. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity . 1999 Jul;11(1):57-65.
  166. Kamath AB , Wang L, et al. Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci U S A . 2003 May 13;100(10):6009-14.
  167. Lee YS, Han CH, et al. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. Int J Urol. 2005 Apr;12(4):383-9.
  168. Maeyama R, Kwon IK, et al. Novel bactericidal surface: catechin-loaded surface-erodible polymer prevents biofilm formation. J Biomed Mater Res A. 2005 Oct 1;75(1)146-55.
  169. Arakawa H, Maeda M, et al. Role of hydrogen peroxide in bactericidal action of catechin . Biol Pharm Bull. 2004 Mar;27(3):277-81.
  170. Yamamoto Y, Matsunaga K, et al. Protective effects of green tea catechins on alveolar macrophages against bacterial infections. Biofactors. 2004;21(1-4):119-21.
  171. Tzianabos A O, Cisneros R L. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann N Y Acad Sci. 1996;797:285–287
  172. Kournikakis B, Mandeville R, Brousseau P, Ostroff G. Anthrax-protective effects of yeast beta 1,3 glucans. MedGenMed. 2003 Mar 21;5(1):1.
  173. Kernodle DS, Gates H, Kaiser AB. Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother. 1998 Mar;42(3):545-9.
  174. Onderdonk AB, Cisneros RL, Hinkson P, Ostroff G. Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo. Infect Immun. 1992 Apr;60(4):1642-7.
  175. Hetland G, Lovik M, Wiker HG. Protective effect of beta-glucan against mycobacterium bovis, BCG infection in BALB/c mice. Scand J Immunol. 1998 Jun;47(6):548-53.
  176. Ji LL, Wang Z, Dong F, Zhang WB, Wang ZT. Andrograpanin, a compound isolated from anti-inflammatory traditional Chinese medicine Andrographis paniculata, enhances chemokine SDF-1alpha-induced leukocytes chemotaxis. J Cell Biochem. 2005 Aug 1;95(5):970-8.
  177. Dias da Silva W, Tambourgi DV. IgY: a promising antibody for use in immunodiagnostic and in immunotherapy. Vet Immunol Immunopathol. 2010 Jun 15;135(3-4):173-80.
  178. Dean KL. Hyperimmune eggs capture natural immune support. Altern Complemen Ther. June 2000;6(3):118-24.
  179. Cama VA, Sterling CR. Hyperimmune hens as a novel source of anti-Cryptosporidium antibodies suitable for passive immune transfer. J Protozool. 1991 Nov-Dec;38(6):42S-43S.
  180. Fujibayashi T, Nakamura M, Tominaga A, et al. Effects of IgY against Candida albicans and Candida spp. Adherence and biofilm formation. Jpn J Infect Dis. 2009 Sep;62(5):337-42.
  181. Sarker SA, Casswall TH, Juneja LR, et al. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2001 Jan;32(1):19-25.
  182. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003 Jun;35(6):433-40.
  183. Xie MQ, Meng YX, Li ZH, et al. Effect of specific immunoglobulin Y in the treatment of acute and chronic pharyngitis. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2004 Feb;39(2):112-5